Prevalence of Metabolic Syndrome 32% in Psoriasis Patients
The global prevalence of metabolic syndrome (MetS) is 32% among patients with psoriasis.
The global prevalence of metabolic syndrome (MetS) is 32% among patients with psoriasis.
Researchers evaluated the clinical characteristics, disease burden, and treatment of patients with peripheral spondyloarthritis with and without psoriasis.
Diagnostic delay is common for patients with psoriasis and is increased for men and with psoriasis in specific areas.
Researchers sought to investigate medication-related adverse psoriasis events excluding drugs already approved by the US Food and Drug Administration to treat psoriatic arthritis or psoriasis.
The efficacy and safety of a once daily oral tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis is assessed.
The role of psoriasis on the health-related quality of life in pediatric patients is investigated.
Researchers sought to determine if psoriasis is associated with greater risk of adverse pregnancy outcomes and if psoriasis severity affects the association.
Researchers explore whether lifestyle is associated with psoriasis onset among individuals with different genetic risk levels.
Researchers investigated the risk for tattoo-related complications among patients with psoriasis.
Psoriasis is associated with nonalcoholic fatty liver disease (NAFLD) in a U.S. outpatient population.